Literature DB >> 28087608

Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer.

Catherine Schairer1, Shahinaz M Gadalla2, Ruth M Pfeiffer2, Steven C Moore2, Eric A Engels2.   

Abstract

Background: Obesity has been associated with substantially higher risk of inflammatory breast cancer (IBC) than other breast cancer. Here, we assess whether comorbidities of obesity, namely diabetes, abnormal glucose, dyslipidemia, and hypertension, are differentially related to risk of IBC and other breast cancers by tumor stage at diagnosis (localized/regional/distant/unstaged).
Methods: We used linked SEER-Medicare data, with female breast cancer cases ages 66+ years identified by SEER registries (years 1992-2011). We divided first breast cancers into IBC (N = 2,306), locally advanced non-IBC (LABC; N = 10,347), and other (N = 197,276). We selected female controls (N = 200,000) from a stratified 5% random sample of Medicare recipients alive and breast cancer free. We assessed exposures until 12 months before diagnosis/selection using Medicare claims data. We estimated odds ratios (OR) and 99.9% confidence intervals (CI) using unconditional logistic regression.
Results: Diabetes was associated with increased risk of distant IBC (98.5% of IBC cases; OR 1.44; 99.9% CI 1.21-1.71), distant (OR 1.24; 99.9% CI, 1.09-1.40) and regional (OR 1.29 (99.9% CI, 1.14-1.45) LABC, and distant (OR 1.23; 99.9% CI, 1.10-1.39) and unstaged (OR 1.32; 99.9% CI, 1.18-1.47) other breast cancers. Dyslipidemia was associated with reduced risk of IBC (OR 0.80; 95% CI, 0.67-0.94) and other breast cancers except localized disease. Results were similar by tumor estrogen receptor status. Abnormal glucose levels and hypertension had little association with risk of any tumor type.Conclusions: Associations with diabetes and dyslipidemia were similar for distant stage IBC and other advanced tumors.Impact: If confirmed, such findings could suggest avenues for prevention. Cancer Epidemiol Biomarkers Prev; 26(6); 862-8. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28087608      PMCID: PMC5575736          DOI: 10.1158/1055-9965.EPI-16-0647

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Science funding: Provocative questions in cancer research.

Authors:  Harold Varmus; Ed Harlow
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

Review 2.  Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.

Authors:  Mukesh K Jain; Paul M Ridker
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 3.  Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.

Authors:  Nathalie Esser; Sylvie Legrand-Poels; Jacques Piette; André J Scheen; Nicolas Paquot
Journal:  Diabetes Res Clin Pract       Date:  2014-04-13       Impact factor: 5.602

4.  Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly.

Authors:  Eric A Engels; Ruth M Pfeiffer; Winnie Ricker; William Wheeler; Ruth Parsons; Joan L Warren
Journal:  Am J Epidemiol       Date:  2011-08-04       Impact factor: 4.897

Review 5.  The role of inflammation in inflammatory breast cancer.

Authors:  Tamer M Fouad; Takahiro Kogawa; James M Reuben; Naoto T Ueno
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

6.  Risk factors for inflammatory breast cancer and other invasive breast cancers.

Authors:  Catherine Schairer; Yan Li; Peter Frawley; Barry I Graubard; Robert D Wellman; Diana S M Buist; Karla Kerlikowske; Tracy L Onega; William F Anderson; Diana L Miglioretti
Journal:  J Natl Cancer Inst       Date:  2013-09-18       Impact factor: 13.506

7.  Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.

Authors:  Reiko Suzuki; Nicola Orsini; Shigehira Saji; Timothy J Key; Alicja Wolk
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

Review 8.  Diabetes medications: Impact on inflammation and wound healing.

Authors:  Jay J Salazar; William J Ennis; Timothy J Koh
Journal:  J Diabetes Complications       Date:  2015-12-19       Impact factor: 2.852

9.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?

Authors:  William F Anderson; Kenneth C Chu; Shine Chang
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

Review 10.  Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.

Authors:  Oystein Karlstad; Jacob Starup-Linde; Peter Vestergaard; Vidar Hjellvik; Marloes T Bazelier; Marjanka K Schmidt; Morten Andersen; Anssi Auvinen; Jari Haukka; Kari Furu; Frank de Vries; Marie L De Bruin
Journal:  Curr Drug Saf       Date:  2013-11
View more
  10 in total

1.  Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer.

Authors:  Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

2.  Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.

Authors:  Catherine Schairer; Ruth M Pfeiffer; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-24       Impact factor: 7.396

3.  Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).

Authors:  Sarah J Aurit; Susan S Devesa; Amr S Soliman; Catherine Schairer
Journal:  Breast Cancer Res Treat       Date:  2019-03-26       Impact factor: 4.872

4.  Association between chronic kidney disease and cancer including the mortality of cancer patients: national health and nutrition examination survey 1999-2014.

Authors:  Kanglin Guo; Zufeng Wang; Ran Luo; Yichun Cheng; Shuwang Ge; Gang Xu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

5.  Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study.

Authors:  Catherine Schairer; Cecile A Laurent; Lisa M Moy; Gretchen L Gierach; Neil E Caporaso; Ruth M Pfeiffer; Lawrence H Kushi
Journal:  Breast Cancer Res Treat       Date:  2020-07-20       Impact factor: 4.872

6.  Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.

Authors:  Catherine Schairer; D Michal Freedman; Shahinaz M Gadalla; Ruth M Pfeiffer
Journal:  Breast Cancer Res Treat       Date:  2018-02-15       Impact factor: 4.872

7.  Diabetes mellitus and cancer incidence: the Atherosclerosis Risk in Communities (ARIC) cohort study.

Authors:  Hadith Rastad; Mahboubeh Parsaeian; Nooshin Shirzad; Mohammad Ali Mansournia; Kamran Yazdani
Journal:  J Diabetes Metab Disord       Date:  2019-05-16

8.  A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population.

Authors:  Pei Yang; Hesham Elhalawani; Yingrui Shi; Ying Tang; Yaqian Han; Yu Zhao; Fan Lou; Hekun Jin
Journal:  Oncotarget       Date:  2017-04-27

9.  Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea.

Authors:  Kyu-Tae Han; Seungju Kim
Journal:  BMC Cancer       Date:  2022-02-08       Impact factor: 4.430

10.  Hypertension predicts a poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Jie Liang; Guodong Li; Jun Xu; Tong Wang; Yanyan Jia; Qinghua Zhai; Lihua Qiao; Miao Chen; Yajing Guo; Shujun Zhang
Journal:  Oncotarget       Date:  2018-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.